-- Helius Medical and Shepherd Center partner on a study that aims at rehabilitating walking mobility in people recovering from stroke ---- Shepherd Center, a top neurorehabilitation hospital, is the third site in Helius’ U.S. registrational program for Portable Neuromodulation Stimulator (PoNS®) in stroke ---- The single-arm study will evaluate PoNS in treating gait and balance deficits in chronic stroke survivors ---- Regulatory submission seeking marketing authorization for stroke expected in
-- Lovell is an approved supplier to the U.S. Department of Veterans Affairs (VA) and Department of Defense (DoD) ---- Over 28,000 cases of multiple sclerosis (MS) are reported to the VA annually -- NEWTOWN, Pa., April 03, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced it has partnered with Lovell Government S
Helius Medical Technologies, Inc. (NASDAQ:HSDT) Q4 2023 Earnings Call Transcript March 28, 2024 Helius Medical Technologies, Inc. beats earnings expectations. Reported EPS is $-1.47, expectations were $-4.05. HSDT isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, and thank […]